drugset
drugset / Trial / NCT03356600

Apatinib Plus Radiotherapy for Patients With Brain Metastases From Non-small-cell Lung Cancer

NCT03356600 ↗

Phase 2 Unknown 44 enrolled Shanxi Province Cancer Hospital
NaSingle-groupOpen-labelTreatment

Summary

To observe the effectiveness and safety of apatinib combined with radiotherapy for brain metastasis from non-small cell lung cancer patients

Timeline

Start
2017-12
Primary completion
2019-01
Completion
2019-10

Drugs

EvaluationDrugModalityDoseRoute
Subject Rivoceranib Small molecule 500 mg —

Indications

metastatic malignant neoplasm in the brain